Published
June 19, 2026
Not long ago, patients with severe obesity faced a stark choice: major surgery or a lifetime of managing a condition that medicine had largely given up on. Today, that has changed. A new generation of anti-obesity medicines—including GLP-1 therapies—are delivering meaningful, lasting weight loss while reducing the risk of heart disease, diabetes, and other life-threatening complications. For the roughly 42% of U.S. adults living with obesity, it's a transformation that touches every community and every workplace.
It's the employee who avoided a diabetes diagnosis. The parent who finally has enough energy to keep up with their kids. The older adult who gets to actually enjoy retirement. These medicines are the result of decades of research, rigorous clinical trials, and sustained private investment in one of the hardest health problems we've ever faced. The results are only beginning to be felt, and the potential is enormous.
The Numbers Behind the Breakthrough
A University of Chicago analysis commissioned by the U.S. Chamber recently quantified what medical innovation actually delivers. Across four disease areas—HIV, heart disease, breast cancer, and obesity—the study estimates that innovation has generated $167.5 trillion in total societal value over a 30-year horizon, accounting for longer lives, better quality of life, productivity gains, and stronger federal tax revenues.
Obesity is a major driver of those projected gains. Clinical trials for leading GLP-1 therapies have shown reductions in major cardiovascular events of up to 20%—a meaningful shift in the trajectory of a disease that has long been a leading driver of heart attacks, strokes, and early death. Using standard government cost-benefit methodologies, the estimated health value from obesity innovation alone reaches $94.4 trillion over 30 years, with treatments projected to add nearly a year of life for millions of Americans even in the early stages of their impact.
Behind those numbers are real moments: more time with family, fewer debilitating complications, more people living independently.
Healthier People, Stronger Communities
When people are healthier, the benefits ripple outward in ways that are hard to fully capture in a spreadsheet. The analysis projects $6.48 trillion in productivity gains tied to obesity innovations over 30 years, but those numbers reflect something more personal: people with more energy, fewer chronic complications, and more years of good health ahead of them. They're coaching little league, staying active in their communities, and doing the things that make life worth living.
There's a fiscal dimension too. The analysis projects $1.53 trillion in additional federal tax revenue over that same period, and $574 billion in downstream health spending savings across all four disease areas studied. Effective treatment tends to prevent the kind of severe complications that drive the highest costs, for patients and the system alike.
Progress Didn't Happen by Accident
The American innovation model rewards risk-taking, protects intellectual property, and funds the long, expensive road from discovery to approved treatment. That's worth protecting.
That’s why proposals like Most-Favored Nation (MFN) pricing deserve serious scrutiny. Tying U.S. drug prices to those set by foreign governments might sound like a reasonable shortcut, but it would erode the incentives that make high-risk R&D viable. MFN-style pricing could reduce U.S. life sciences R&D spending by 18.5% and cut clinical trial activity by up to 75%. Fewer trials means fewer breakthroughs, and patients waiting longer for treatments that may never come.
The Right Way to Expand Access
Affordability is a real and legitimate concern, and it deserves a real answer. Employer health plans, expanded coverage options, and competitive market dynamics are all tools that can bring these treatments within reach for more patients without dismantling the system that produced them. What won't work is importing foreign price controls that other countries use precisely because they can free ride on American R&D investment. That's not a solution; it's a shortcut that future patients will pay for in treatments never developed and breakthroughs never reached.
Obesity innovation is showing what's possible when policy supports discovery, development, and delivery. We should build on that momentum, not undermine it. Patients, families, employers, and communities all benefit when America remains the best place in the world to develop and to receive the next generation of treatments. The cost of curing disease is far less than the cost of enduring it.
About the author
Brad Watts
Brad Watts is the Senior Vice President at the U.S. Chamber of Commerce's Global Innovation Policy Center (GIPC). He works with U.S. Chamber members to foster a political, legal, and economic environment where innovators and creators can invest in the next big thing for the benefit of Americans and the world.
